vabametkib (ABN401) / Abion 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
vabametkib (ABN401) / Abion
NCT05882292: A Phase II Study of ABN401 in Advanced Solid Tumors With c-MET Gene Aberration

Not yet recruiting
2
20
NA
ABN401, c-MET inhibitor
Yonsei University
Neoplasms
12/24
12/24
NCT05541822: To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation

Recruiting
2
40
US, RoW
ABN401
Abion Inc
Advanced Solid Tumors
04/25
08/25
NCT04052971: To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer Harboring c-MET Dysregulation

Recruiting
1
78
RoW
ABN401- Escalation Phase, ABN401- Expansion Phase
Abion Inc, Novotech (Australia) Pty Limited
Advanced Solid Tumors
12/24
12/24
NCT05248074: To Evaluate the Safety, Pharmacokinetic and the Effect of Food After Administration of ABN401 in Healthy Adult Volunteers

Completed
1
25
RoW
High-fat meal (over 900 kcal), ABN401 (investigational product)
Abion Inc
Solid Tumor
02/22
10/22

Download Options